Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
AVI Polymers hit a 5% upper circuit for the 15th straight session. The move follows the launch of its healthcare AI platform Ashwini.tech and a proposed ₹500 crore acquisition. Early user traction and a SaaS revenue roadmap have added to market interest, even as near-term revenue contribution remains limited.
On May 6, 2026, AVI Polymers share price is in focus as the stock hit the 5% upper circuit limit for the fifteenth consecutive day. The trading volume for AVI Polymers was recorded as 46.3 lakhs against an average of 33.6 lakhs over the last thirty days. This trend in reaching the upper circuit has been triggered by a number of events from the company.
The company has launched its health care AI platform called Ashwini.tech, a board meeting on May 7, 2026, to discuss the acquisition worth ₹500 crores, and a statement regarding the progress made by its early users and SaaS revenue model.
On April 30, 2026, AVI Polymers made an announcement that its flagship personal healthcare AI platform, branded AVI Health AI and operating at ashwini.tech, is now officially live and operational. The platform has been developed by the company's wholly-owned technology subsidiary.
A subsequent announcement provided a business update on early adoption, disclosing that since the soft launch, the platform has registered a waitlist of over 5,620 users through what the company describes as organic traction. The announcement presents this as validation of the company's pivot into scalable digital platforms.
The platform operates on three stated capabilities: real-time wellness analytics for continuous preventive health tracking; diagnostic assistance through multimodal AI tools; and a Health-as-a-Service, or HaaS, architecture designed for rapid user acquisition and scale.
The announcement lays out a monetisation framework built around an annual subscription priced at ₹999 per user per year. Based on the SaaS industry average rate of subscription conversion at 8%-15%, the company estimates having a first-year cohort of around 600 to 900 paying users, amounting to about ₹6 lakhs to ₹9 lakhs ARR.
The company has also outlined a two-phase growth target. Phase 1 aims to scale the active user base to approximately 10,000 paying subscribers, which it says would unlock a ₹1 crore ARR run-rate and formally position Ashwini Healthcare AI among early-stage SaaS platforms in the Indian market. Phase 2 sets a more ambitious target of 80,000 to 1,20,000 paying subscribers, which the company projects would generate ₹8 crore to ₹12 crore in ARR. The filing describes this scale as meeting standard Series-A valuation metrics.
On retention, the platform's internal operational target is an annual retention rate of 65% to 70%, which the company says is characteristic of top-tier health and wellness ecosystems.
What makes the Ashwini.tech launch significant in the context of AVI Polymers is that it completes what the company is calling its dual-engine AI strategy. The company already has an agritech platform, KrishiBuddy, described as live and scaling. With Ashwini.tech now operational, AVI Polymers is presenting itself as a company positioned at the intersection of two growing digital markets: AgriTech and HealthTech.
The technology deployment has been funded from what the company describes as a zero-debt balance sheet, supplemented by a recent capital infusion of ₹89.99 crore. Monetisation of the ecosystem is targeted for FY27. The filings also reference the company's ₹312.11 crore FY26 revenue milestone as a foundation from which the digital pivot is being built.
Separately, AVI Polymers made an announcement confirming a board meeting on Thursday, May 7, 2026. The agenda includes evaluating a fund-raising proposal through qualified institutional placement, private placement, preferential issue, or any other permissible mode.
What has attracted the attention of the market is the valuation of the transaction, which is around ₹500 crore. As per the notice, this is only indicative and will depend on the outcome of the due diligence process and the approval from the relevant regulatory authorities. It will also explore the possible ways of acquisition through shares or any other permissible route.
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading